Published on : Feb 22, 2016
Albany, New York, February 18, 2016: In the past decade or so, the treatment of type 2 diabetes mellitus has been revolutionized, especially thanks to the use of new therapies. The report studying the type 2 diabetes mellitus therapeutics market in Asia Pacific is recently added to ResearchMoz.us. This 66-page research publication is titled “Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth.”
Diabetes mellitus is characterized by high blood glucose levels and chronic hyperglycemia resulting from defects in insulin action and/or insulin secretion. Chronic hyperglycemia is associated with the long-term dysfunction, failure, and damage of multiple organs such as the kidneys, heart, eyes, and blood vessels. Patients of diabetes mellitus can be categorized as having either type 1 diabetes mellitus and type 2 diabetes mellitus. A whopping 85-95% of all diabetics fall into the latter category.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=556848
The treatment of type 2 diabetes mellitus comprises a wide range of marketed products including sulfonylureas, GLP-1 receptor agonist, SGLT-2 inhibitor, biguanide, thiazolidinediones, DPP-4 inhibitor, and insulin therapies. Even with the availability of these therapies, there is a massive patient base and significant unmet need for products that can prevent and cure diabetic complications such as diabetic retinopathy, nephropathy, and cardiovascular diseases. Products that can provide improved glycemic control are also in great demand.
The Asia Pacific type 2 diabetes mellitus therapeutics market is projected to expand at a 7.70% CAGR from 2012 to 2021, rising from a value of over US$6 bn to US$10.2 bn. This growth can be attributed to the uptake of newer therapies and the surging prevalence of type 2 diabetes mellitus. Overcoming the sales erosion of generic therapies resulting from the expirations of several patents, the type 2 diabetes mellitus therapeutics market is projected to witness significant market growth in the coming years. The Asia Pacific market currently comprises a number of novel products including Victoza, a GLP-1 receptor agonist; Jardiance, an SGLT-2 inhibitor; and Galvus, a DPP-4 inhibitor.
The report on the Asia Pacific type 2 diabetes mellitus therapeutics market addresses a number of relevant questions, the answers to which can greatly benefit all those involved in the market. Some of the most important aspects that the report addresses are the competitive advantages of the current novel drugs, the failure rates varying by molecule type, product stage, and mechanism of action, the various trends in the market, the impact of patent expirations on the market, the entry of new players and the changes they might lead to, the level of unmet needs across the region, the existing pipeline of novel drugs and their potential, the annual cost of type 2 diabetes mellitus therapy, the commercial success of existing drugs, and the risks associated with different therapies.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com